| SCHRODER ISF ASIAN OPPORTUNITIES B ACC EUR | RVI ASIA EX-JAPÓN | 58,02% | 68,04% | 36,82% | 160,97% |
| JPM THEMATICS-GENETIC THERAPIES C2 (DIST) USD | RVI BIOTECNOLOGÍA | 57,96% | 22,49% | -22,88% | · |
| BNP PARIBAS EMERGING EQUITY N CAP | RVI EMERGENTES | 57,95% | 83,91% | 37,51% | 81,26% |
| JPM EMERGING MARKETS EQUITY A (DIST) GBP | RVI EMERGENTES | 57,87% | 69,30% | 25,38% | 148,63% |
| JPM THEMATICS-GENETIC THERAPIES I (ACC) EUR | RVI BIOTECNOLOGÍA | 57,84% | 23,56% | -22,40% | · |
| BGF EMERGING MARKETS SUSTAINABLE EQUITY X2 USD | RVI EMERGENTES | 57,80% | 76,58% | 51,64% | · |
| JPM THEMATICS-GENETIC THERAPIES A (ACC) USD | RVI BIOTECNOLOGÍA | 57,75% | 21,86% | -23,84% | · |
| ABRDN SICAV I-FUTURE MINERALS FUND S ACC USD | RVI MATERIAS PRIMAS | 57,74% | 47,11% | 59,68% | 148,91% |
| JPM ASIA GROWTH A (ACC) USD | RVI ASIA EX-JAPÓN CRECIMIENTO | 57,74% | 67,78% | 26,52% | 183,62% |
| JPM JAPAN STRATEGIC VALUE I (ACC) EUR (HEDGED) | RVI JAPÓN VALOR | 57,73% | 141,31% | 211,44% | · |
